Man Group plc Makes New Investment in AtriCure, Inc. $ATRC

Man Group plc acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 24,443 shares of the medical device company’s stock, valued at approximately $684,000.

Other large investors also recently modified their holdings of the company. Bank of America Corp DE lifted its stake in AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after purchasing an additional 92,830 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in AtriCure in the second quarter valued at approximately $1,744,000. Rice Hall James & Associates LLC bought a new position in shares of AtriCure in the second quarter worth about $3,755,000. F m Investments LLC acquired a new stake in shares of AtriCure during the fourth quarter valued at about $2,872,000. Finally, Vanguard Group Inc. increased its holdings in AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after purchasing an additional 62,861 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Justin Noznesky sold 6,182 shares of AtriCure stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the sale, the insider directly owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider owned 86,511 shares in the company, valued at $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 53,616 shares of company stock valued at $2,149,994. 4.00% of the stock is owned by corporate insiders.

AtriCure Trading Down 0.2%

AtriCure stock opened at $52.46 on Friday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of 249.82 and a beta of 1.26. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $53.50. The business’s fifty day simple moving average is $39.67 and its two-hundred day simple moving average is $32.70.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Needham & Company LLC increased their price target on AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday. Raymond James Financial set a $52.00 target price on AtriCure in a report on Tuesday, July 21st. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Finally, Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.